Amgen Inc. (AMGN): Price and Financial Metrics

Amgen Inc. (AMGN): $262.75

1.32 (-0.50%)

POWR Rating

Component Grades








Add AMGN to Watchlist
Sign Up

Industry: Biotech




#47 of 362

in industry

AMGN Price/Volume Stats

Current price $262.75 52-week high $329.72
Prev. close $264.07 52-week low $211.71
Day low $262.58 Volume 2,082,700
Day high $265.92 Avg. volume 2,851,969
50-day MA $277.80 Dividend yield 3.39%
200-day MA $271.42 Market Cap 140.81B

AMGN Stock Price Chart Interactive Chart >

Amgen Inc. (AMGN) Company Bio

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology. (Source:Wikipedia)  

AMGN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMGN Latest Social Stream

Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about AMGEN INC that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Yahoo | December 28, 2023

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

Yahoo | December 28, 2023

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.

Yahoo | December 27, 2023

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Yahoo | December 27, 2023

FDA Wants Another Amgen Study on Lumakras

Amgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras. Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned away its application seeking full approval and called on the company to complete the additional study by February 2028. An FDA advisory panel in October raised issues with Amgen's previous confirmatory study, citing problems with how the study was conducted, its small size and relatively minor extension of the time that patients lived without their cancers getting worse.

Yahoo | December 26, 2023

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo -3.77%
3-mo -13.97%
6-mo -4.28%
1-year 11.55%
3-year 11.61%
5-year 72.52%
YTD -8.06%
2023 13.46%
2022 20.43%
2021 0.87%
2020 -1.99%
2019 27.60%

AMGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!